Development of chemopreventie agent for pancreatic cancer using Connectivity Map analysis

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K17400
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: The University of Tokushima
• Principal Investigator: FUJINO Yasuteru 徳島大学, 大学院医歯薬学研究部(医学域), 助教 (60747442)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 膵癌予防薬 / IPMN / 癌予防 / 薬理学

Outline of Final Research Achievements

We performed microarray analysis of human IPMN and Pancreatic cancer tissues as well as of normal pancreatic tissue, and determined gene expression signature in each lesion. Applying the gene signature data for connectivy map analysis which includes the data of all existing drugs, we chose candidate preventive drugs, which are expected to normalize gene expression profile of those lesions. We then established organoid from human IPMN and pancreatic cancer tissues respectively, and screened candidate drugs to evaluate inhibitory effects of candidate preventive drugs.The most effective drugs for tumor have been chosen. When some of the drugs were administered to rat chemical carcinogeneis model, numbers of tumors were significantly inhibited. Currently, we planning a clinical trial for these drugs to evaluate inhibitory effect on IPMN or pancreatic cancer in human.

Free Research Field

消化器内科学

Academic Significance and Societal Importance of the Research Achievements

これまでに、既存の薬剤を網羅的に解析して、IPMNや膵癌に対する予防薬を探索した研究は無く、本研究が初めてである。本研究では、IPMNや膵癌に対する予防候補薬を抽出し、in vitroで有効な薬剤を絞り込み、in vivoで有効性の高い薬剤を絞り込むことができた。また、既存の薬剤を対象にしているので、速やかに臨床試験に進むことができるという利点がある。また、本研究はdrug repositioningの観点からも重要性が高い。